Skip to content
About CombiGene
Projects
The pain program COZY
The epilepsy project CG01
Patent
The Market
Organization
Investors
Financial reports
Prospectus/IM
Financial calendar
Company and share information
Nasdaq First North Growth Market
Corporate governance
Organization
Articles of association (SE)
Company description (SE)
IR-contact
Certified Adviser
Media
Press releases
Presentations
Ingeneious
Calendar
Contact
Contact us
Downloads
About CombiGene
Projects
The pain program COZY
The epilepsy project CG01
Patent
The Market
Organization
Investors
Financial reports
Prospectus/IM
Financial calendar
Company and share information
Nasdaq First North Growth Market
Corporate governance
Organization
Articles of association (SE)
Company description (SE)
IR-contact
Certified Adviser
Media
Press releases
Presentations
Ingeneious
Calendar
Contact
Contact us
Downloads
SV
January 29, Lund Aktiedagen
December 11, 2018
Share
News
December 2, 2024
CombiGene conducts Extraordinary General Meeting
November 14, 2024
Shareholders’ proposal for election of Board of Directors
November 8, 2024
Interim report January – September 2024 for CombiGene AB (publ)
November 1, 2024
NOTICE OF EXTRAORDINARY GENERAL MEETING IN COMBIGENE AB (PUBL)
October 31, 2024
The Board of Directors of CombiGene has received proposals from the Company’s largest shareholder for the Extraordinary General Meeting intended to be convened
October 28, 2024
CombiGene Initiates Measures to Extend Liquidity Horizon by Sharpening Strategic Focus on Gene Therapy, Prioritizing Pipeline Assets, and Implementing a Cost Reduction Program
September 30, 2024
CombiGene announces new preclinical research results in the epilepsy project
August 23, 2024
Interim report January – June 2024 for CombiGene AB (publ)
Load more
We use cookies to ensure that we give you the best experience on our website. If you continue to use this website, we will assume that you accept it.
Ok
Privacy policy
